20250515-Jefferies-PRAX,LQDA,ARQT,EYPT（PRAX）_今年春天有望蓬勃发展的四只股票PRAX_LQDA_ARQT_EYPT快速视频_5分钟_8页_810kb

Biotech Stock Recommendations Summary

Overview

Jefferies analyst Kambiz Yazdi recommends four biotechnology stocks—PRAX (Praxis Precision Medicines, Inc.), LQDA (Liquidia Corporation), ARQT (Arcutis Biotherapeutics Inc.), and EYPT (EyePoint Pharmaceuticals Inc.)—for potential investment, highlighting them as opportunities to "thrive" in the current market. The analysis is presented in a video format, with time stamps for each stock's discussion.

Analyst Recommendations

• All stocks are rated "Buy," with associated price targets:
  • PRAX: $37.10
  • LQDA: $18.65
  • ARQT: $13.60
  • EYPT: $5.49
• The recommendations are based on a Discounted Cash Flow (DCF) valuation model.

Key Companies and Risks

• PRAX (Praxis Precision Medicines): Focuses on precision medicines; key risks include clinical trial failures, regulatory hurdles, commercial competition, and funding needs.
• LQDA (Liquidia Corporation): Involves drug delivery technologies; risks encompass clinical, regulatory, legal, and commercial challenges, similar to PRAX.
• ARQT (Arcutis Biotherapeutics): Develops treatments for eczema; commercial risks include market competition, funding requirements, and payer coverage issues.
• EYPT (EyePoint Pharmaceuticals): Concentrates on ophthalmology therapies; primary risks are clinical trial outcomes, regulatory approvals, commercial traction, and capital requirements.

Analyst Certification

Kambiz Yazdi certifies that the views expressed accurately reflect his personal analysis. Jefferies LLC manages potential conflicts of interest, as it expects compensation from these companies for investment banking services.

Video Component

The analysis is delivered through a video recommendation under 5 minutes, available via the provided link. Time stamps guide the viewer: [00:10] PRAX, [01:25] LQDA, [02:15] ARQT, [03:30] EYPT.

Important Notes

• These recommendations are not guarantees; past performance does not predict future results, and investments may fluctuate. Legal disclosures emphasize Jefferies' conflicts of interest and the impersonal nature of equity research.